ACM
WHWK

ADAR1 Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

ADAR1 Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.14M Buy
1,341,394
+1,212,891
+944% +$5.05M 0.28% 81
2026
Q1 		$443K Buy
128,503
+50,910
+66% +$159K 0.03% 212
2025
Q4 		$188K Buy
+77,593
New +$178K 0.01% 231

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ADAR1 Capital Management's WHWK Position: Q2 2026 in Review

ADAR1 Capital Management increased its Whitehawk Therapeutics (WHWK) stake by 944% in Q2 2026, buying an estimated $5.05M and bringing the position to 1,341,394 shares worth $6.14M. The position accounts for 0.28% of the portfolio, ranked #81.

ADAR1 Capital Management first reported a position in WHWK in Q4 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • ADAR1 Capital Management held 1,341,394 shares of Whitehawk Therapeutics worth $6.14M as of Q2 2026.
  • ADAR1 Capital Management bought 1,212,891 Whitehawk Therapeutics shares in Q2 2026, an estimated $5.05M.
  • Whitehawk Therapeutics made up 0.28% of ADAR1 Capital Management's portfolio in Q2 2026, its #81 holding.
  • ADAR1 Capital Management first reported a position in Whitehawk Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.